Comparison between coagulation factor VIII quantified with one‐stage activity assay and with mass spectrometry in haemophilia A patients: Proof of principle.

Autor: Donners, Anouk A. M. T.¹ a.a.m.donners@umcutrecht.nl, Maarseveen, Erik M.¹, Weetink, Yrea R. J.¹, El Amrani, Mohsin^1,2, Fischer, Kathelijn³, Rademaker, Carin M. A.¹, Egberts, Toine C. G.^1,4, Huisman, Albert², Musson, Ruben E. A.²

Publikováno v: International Journal of Laboratory Hematology. Dec2020, Vol. 42 Issue 6, p819-826. 8p.

Quantification of emicizumab by mass spectrometry in plasma of people with hemophilia A: A method validation study

Autor: Donners, Anouk A. M. T., Gerencsér, László, Elst, Kim C. M. van der, Egberts, Toine C. G., Maat, Moniek P. M. de, Huisman, Albert, Urbanus, Rolf T., Amrani, Mohsin El, Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology

Publikováno v: Research and Practice in Thrombosis and Haemostasis, 6(4), 1
Research and Practice in Thrombosis and Haemostasis, 6(4):e12725. Wiley-Blackwell Publishing Ltd

Background: Emicizumab is a new treatment option for people with hemophilia A. Emicizumab was approved with a body-weight-based dosage regimen, without laboratory monitoring requirements. Guidelines, however, recommend measuring emicizumab concentrat

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7d5e45434d8674977b580214c4c9952f
https://pubmed.ncbi.nlm.nih.gov/35702589

Comparison between coagulation factor VIII quantified with one-stage activity assay and with mass spectrometry in haemophilia A patients: Proof of principle

Autor: Donners, Anouk A M T, van Maarseveen, Erik M, Weetink, Yrea R J, El Amrani, Mohsin, Fischer, Kathelijn, Rademaker, Carin M A, Egberts, Toine C G, Huisman, Albert, Musson, Ruben E A

INTRODUCTION: Haemophilia A is a hereditary bleeding disorder caused by a factor VIII (FVIII) deficiency. As biomarker, FVIII activity is used to classify disease severity and to monitor treatment. The one-stage clotting assay (OSA) is performed to m

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od_______101::2907a6c85ce27cb4963aecb15c9a5c0c
https://dspace.library.uu.nl/handle/1874/410237

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Pharmacokinetics and Associated Efficacy of Emicizumab in Humans: A Systematic Review.

Autor: Donners AAMT; Department of Clinical Pharmacy, University Medical Center Utrecht, Utrecht University, D.00.204, Postbus 85500, 3508 GA, Utrecht, The Netherlands. a.a.m.donners@umcutrecht.nl., Rademaker CMA; Department of Clinical Pharmacy, University Medical Center Utrecht, Utrecht University, D.00.204, Postbus 85500, 3508 GA, Utrecht, The Netherlands., Bevers LAH; Department of Clinical Pharmacy, University Medical Center Utrecht, Utrecht University, D.00.204, Postbus 85500, 3508 GA, Utrecht, The Netherlands., Huitema ADR; Department of Clinical Pharmacy, University Medical Center Utrecht, Utrecht University, D.00.204, Postbus 85500, 3508 GA, Utrecht, The Netherlands.; Department of Pharmacy and Pharmacology, Netherlands Cancer Institute, Amsterdam, The Netherlands.; Department of Pharmacology, Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands., Schutgens REG; Van Creveldkliniek, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands., Egberts TCG; Department of Clinical Pharmacy, University Medical Center Utrecht, Utrecht University, D.00.204, Postbus 85500, 3508 GA, Utrecht, The Netherlands.; Department of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Faculty of Science, Utrecht University, Utrecht, The Netherlands., Fischer K; Van Creveldkliniek, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.

Publikováno v: Clinical pharmacokinetics [Clin Pharmacokinet] 2021 Nov; Vol. 60 (11), pp. 1395-1406. Date of Electronic Publication: 2021 Aug 13.